Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Geoffrey Connors MD, FACP
Geoffrey R. Connors MD, FACP Associate Editor
Shyoko Honiden MD, MSc
Shyoko Honiden MD, MSc Editor-in-Chief
Virginia Brady MD
Virginia A. Brady MD Associate Editor
See All Experts
featured
Published in Respiratory Medicine

Expert Opinion / Commentary · December 10, 2020

2020 Top Stories in Respiratory Medicine: The CAPTAIN and IRIDIUM Trials

Geoffrey Connors MD, FACP

 

 Save  Recommend
 Share

Additional Info

  1. Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY). Lancet. 2016;388(10048):963-973.
  2. Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671-1680.
  3. Papi A, Vestbo J, Fabbri L, et al. Extra fine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076-1084.
  4. Kerstjens HA, Disse B, Schröder-Babo W, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol. 2011;128(2):308.
  5. Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367(13):1198-1207.
  6. Virchow JC, Kuna P, Paggiaro P, et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet. 2019; 394(10210):1737-1749.
  7. Lee LA, Bailes Z, Barnes N, et al. Efficacy and safety of once-daily singleinhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med. 2020 Sep 9. doi: 10.1016/S2213-2600(20)30389-1. Online ahead of print.
  8. Kerstjens HAM, Maspero J, Chapman KR, et al; IRIDIUM Trial Investigators. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir Med. 2020;8(10):1000-1012.

Further Reading

Most Read This Week

Recently Updated